BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31428295)

  • 1. Correlate the
    Lyu H; Li M; Jiang Z; Liu Z; Wang X
    Comput Struct Biotechnol J; 2019; 17():1020-1030. PubMed ID: 31428295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
    Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtyping of head and neck squamous cell cancers based on immune signatures.
    Song D; Lyu H; Feng Q; Luo J; Li L; Wang X
    Int Immunopharmacol; 2021 Oct; 99():108007. PubMed ID: 34332341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting therapeutic responses in head and neck squamous cell carcinoma from
    Wei M; Zhi J; Li L; Wang W
    Transl Cancer Res; 2023 Dec; 12(12):3604-3617. PubMed ID: 38197078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    Transl Oncol; 2018 Oct; 11(5):1171-1187. PubMed ID: 30059832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients.
    Sacconi A; Muti P; Pulito C; Urbani G; Allegretti M; Pellini R; Mehterov N; Ben-David U; Strano S; Bossi P; Blandino G
    Mol Cancer; 2023 Nov; 22(1):192. PubMed ID: 38031025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.
    Wichmann G; Rosolowski M; Krohn K; Kreuz M; Boehm A; Reiche A; Scharrer U; Halama D; Bertolini J; Bauer U; Holzinger D; Pawlita M; Hess J; Engel C; Hasenclever D; Scholz M; Ahnert P; Kirsten H; Hemprich A; Wittekind C; Herbarth O; Horn F; Dietz A; Loeffler M;
    Int J Cancer; 2015 Dec; 137(12):2846-57. PubMed ID: 26095926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
    JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations.
    Tuna M; Amos CI; Mills GB
    Neoplasia; 2019 Feb; 21(2):197-205. PubMed ID: 30616092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.
    Lindenbergh-van der Plas M; Brakenhoff RH; Kuik DJ; Buijze M; Bloemena E; Snijders PJ; Leemans CR; Braakhuis BJ
    Clin Cancer Res; 2011 Jun; 17(11):3733-41. PubMed ID: 21467160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.